First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12 months and 5 years of age

BACKGROUND: There is a demand of affordable IPV in the World. Statens Serum Institut (SSI) has developed three reduced dose IPV formulations adsorbed to aluminium hydroxide; 1/3 IPV-Al, 1/5 IPV-Al and 1/10 IPV-Al SSI, and now report the results of the first investigations in humans. METHODS: 240 Dan...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindgren, Line M., Tingskov, Pernille N., Justesen, Annette H., Nedergaard, Bettina S., Olsen, Klaus J., Andreasen, Lars V., Kromann, Ingrid, Sørensen, Charlotte, Dietrich, Jes, Thierry-Carstensen, Birgit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5267481/
https://www.ncbi.nlm.nih.gov/pubmed/28027810
http://dx.doi.org/10.1016/j.vaccine.2016.12.027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5267481/
https://www.ncbi.nlm.nih.gov/pubmed/28027810
http://dx.doi.org/10.1016/j.vaccine.2016.12.027

Ejemplares similares